Open AccessPost-molar Choriocarcinoma Prevention with MTX Treatment of Persistent Trophoblastic Disease
Author(s) -
Kazuo Maeda
Publication year - 2019
Publication title -
journal of clinical cases and reports
Language(s) - English
Resource type - Journals
ISSN - 2582-0435
DOI - 10.46619/joccr.2019.2-1047
Subject(s) - choriocarcinoma , molar pregnancy , methotrexate , human chorionic gonadotropin , medicine , molar , chorioepithelioma , pregnancy , urinary system , trophoblastic tumor , obstetrics , gynecology , gestation , biology , hormone , dentistry , genetics
Aim: Prevention of post molar choriocarcinoma. Methods: 70 mg Methotrexate (MTX) was administered all post molar cases, whose urinary pregnancy test was negative, while 200-300 mg MTX was administered to two persistent trophoblastic disease, whose pregnancy test was positive by human chorionic gonadotropin (hCG). Control was 37 post molar cases, who received no MTX. Post molar examination were repeated in both groups. Results: No choriocarcinoma developed in 107 MTX group, while 3 cases developed choriocarcinoma in 37 nonMTX group. Choriocarcinoma case number was significantly less in MTX groups.